WithdrawnNot Applicable

Evaluation of AcrySof IQ Vivity Extended Vision Intraocular Lenses

Stopped: Management decision

United States0Started 2025-06

Plain-language summary

The purpose of this post-market study is to describe the long-term safety and performance of AcrySof IQ Vivity and AcrySof IQ Vivity Toric intraocular lens (IOL) models in a real-world setting through routine clinical practice.

Who can participate

Age range22 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Key Inclusion Criteria: * 22 years old or older at Visit 1. * Able to understand and sign an approved informed consent form. * Implantation of AcrySof IQ Vivity and/or Vivity Toric IOL models in both eyes for 3 to 5 years prior to enrollment. * Documented medical history and required pre-operative baseline information available for retrospective data collection. * Other protocol-specified inclusion criteria may apply. Key Exclusion Criteria: * Corneal refractive surgery after AcrySof Vivity or AcrySof Vivity Toric IOL implantation. * Pregnant or nursing at the time of enrollment. * Childbirth after IOL implantation. * Other protocol-specified exclusion criteria may apply.

What they're measuring

Mean Binocular Best Corrected Distance Visual Acuity (BCDVA) at Visit 1

Timeframe: Visit 1, Year 3-5 postoperative

Incidence of adverse events

Timeframe: Up to Year 3-5 postoperative

Incidence of device deficiencies

Timeframe: Up to Year 3-5 postoperative

Trial details

NCT IDNCT06541795

SponsorAlcon Research

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-12

View on ClinicalTrials.gov More Aphakia trials